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Schizophrenia is a severe psychiatric disorder with a lifetime prevalence of about 1%.
People with schizophrenia have a 4-fold higher prevalence of metabolic syndrome
than the general population, mainly because of antipsychotic treatment but perhaps
also because of decreased physical activity. Metabolic syndrome is a risk factor for
cardiovascular diseases, and the risk of these diseases is 2- to 3-fold higher in
schizophrenia patients than in the general population. The suicide risk is also higher
in schizophrenia, partly as a result of depression, positive, and cognitive symptoms of
the disease. The higher suicide rate and higher rate of cardiac mortality, a consequence
of the increased prevalance of cardiovascular diseases, contribute to the reduced life
expectancy, which is up to 20 years lower than in the general population. Regular
physical activity, especially in combination with psychosocial and dietary interventions,
can improve parameters of the metabolic syndrome and cardiorespiratory fitness.
Furthermore, aerobic exercise has been shown to improve cognitive deficits; total
symptom severity, including positive and negative symptoms; depression; quality of
life; and global functioning. High-intensity interval endurance training is a feasible and
effective way to improve cardiorespiratory fitness and metabolic parameters and has
been established as such in somatic disorders. It may have more beneficial effects on the
metabolic state than more moderate and continuous endurance training methods, but
to date it has not been investigated in schizophrenia patients in controlled, randomized
trials. This review discusses physical training methods to improve cardiorespiratory
fitness and reduce metabolic syndrome risk factors and symptoms in schizophrenia
patients. The results of studies and future high-quality clinical trials are expected to
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lead to the development of an evidence-based physical training program for patients
that includes practical recommendations, such as the optimal length and type of
aerobic exercise programs and the ideal combination of exercise, psychoeducation, and
individual weight management sessions.
Keywords: aerobic exercise, endurance training, high-intensity interval training, metabolic syndrome, mortality,
schizophrenia, cognition, positive and negative symptoms
INTRODUCTION
Schizophrenia is a severe neuropsychiatric disease that affects
∼1% of the population (1, 2). It strikes young adults between 20
and 30 years of age (3), and symptoms persist throughout adult
life in 30–50% of affected patients (4, 5). The disease leads to
impaired social functioning; for example, only 20% of patients
are able to have a job on the primary market, and only about 30%
have a stable relationship (5). Because of the high hospitalization
rates and high levels of both disease-related incapacity to work
and early retirement, schizophrenia-related costs exceed even
those of widespread diseases such as cardiovascular diseases
(CVD) (6). According to the WHO report on the global burden
of disease, schizophrenia is one of the most common conditions
associated with a high rate of years lived with disability (YLD),
one of the leading causes of disease burden (7), and among the 10
most costly illnesses worldwide (8).
COGNITIVE IMPAIRMENT AND
UNDERLYING NEUROBIOLOGICAL
PATHWAYS
Cognitive impairment is a frequent core feature of schizophrenia
(9), in addition to positive and negative symptoms, and is
related to the reported volume loss of the hippocampus, a
region central to memory, learning, and cognitive integration
(10). Cognitive deficits and negative symptoms are the most
important predictors for poor social and functional outcome
and are major contributors to disability (11). Cognitive deficits
are present in domains such as executive function, episodic
memory, attention, and social cognition (11–13), functions that
are particularly dependent on the hippocampus and prefrontal
cortex (14). In schizophrenia, neurodevelopmental disturbances
in vulnerable periods of brain development are thought to
lead to hippocampal-prefrontal pathway deficits, resulting
in the onset of disease symptoms in young adulthood (15).
Meta-analyses of structural magnetic resonance imaging (sMRI)
studies revealed gray matter volume reduction of 5–10% in the
prefrontal cortex and hippocampus in schizophrenia patients
(16). In the polymorph layer of the dentate gyrus (CA4) of
the hippocampus, decreased numbers of oligodendrocytes
(17, 18)—an indicator of disturbed myelination—have been
detected in schizophrenia. A meta-analysis of diffusion-
tensor imaging (DTI) studies in schizophrenia revealed
decreased fractional anisotropy in white matter tracts
interconnecting the prefrontal cortex and hippocampus
(19); such white matter disruption is known to play a crucial
role in cognition and psychopathology (20). Of interest in this
context is that schizophrenia patients with overweight and
obesity showed disturbed white matter integrity, with lower
fractional anisotropy than normal-weight schizophrenia patients
(21).
Several environmental factors, such as psychosocial stress
associated e.g., with an urban lifestyle or childhood trauma,
interact with genetic factors to increase the risk of a chronic
disease course (22). The prefrontal cortex and hippocampus
are central to cognitive processing and are also involved in
the regulation of the neuroendocrine control of stress hormone
secretion, including glucocorticoids (23). Whereas, acute stress
can increase fear-associatedmemory, chronic stress with cortisol-
based stress reactivity levels has a negative impact on spatial-
reference memory and cognitive flexibility, induces hippocampal
volume loss, adversely alters dendritic morphology and reduces
adult neurogenesis and synaptic plasticity (23). Chronic stress
during the pubertal period up to young adulthood, when
synaptic pruning and oligodendrocyte-related myelination take
place, has been shown to induce symptoms of schizophrenia
(24).
MORTALITY IN SCHIZOPHRENIA
Schizophrenia affects daily life and subjective well-being.
Low physical activity, impaired physical health, and reduced
activities of daily living (25, 26) are just some aspects of the
disease. Compared with the general population, individuals
with schizophrenia have a 12-fold higher mortality from all
external causes (27), which can largely be explained by the high
incidence of somatic comorbidities; unhealthy lifestyles, such as
high rates of cigarette smoking and low physical activity; and
increased rate of suicides (26, 28, 29). Estimates indicate that
together these health-related risk factors and suicides reduce life
expectancy by nearly 10–20 years compared with the general
population (30, 31). A meta-analysis of data from 29 countries
on six continents found that mortality was significantly higher
among people with mental disorders and that, in 65 studies,
the highest mortality rate (relative risk 2.54, 95% CI 2.35–
2.75) was among patients with psychosis (31). The relative
risk for natural causes, such as CVD, was 1.80 (95% CI
1.71–1.88), but that for unnatural causes, such as suicides,
was even higher (7.22, 95% CI 6.43–8.12). Cardiovascular
risk was higher in schizophrenia patients than in patients
with depressive disorder or multiple psychiatric diagnoses (32).
People with severe mental illness, including schizophrenia,
had a higher risk of developing coronary heart disease than
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controls (adjusted hazard ratio 1.54; 95% CI 1.30–1.82) and a
higher rate of autonomic nervous system dysfunction, including
diminished heart rate variability, hypertension, alterations of
the QT interval, and lipid pattern abnormalities (33). During
the year after the first diagnosis of psychosis, a study found
that the relative risk for all-cause mortality was 54.6 (95%
CI 41.3–68.0) per 10,000, whereby the highest relative risk
of death was found for self-inflicted injury or poisoning;
during this period, the relative risk of death due to heart
disease or diabetes did not differ between the group of people
with a psychotic disorder and the general outpatient group
(34).
In schizophrenia patients, suicidal thoughts and suicide
planning and attempts were significantly associated with
completed suicide in the following year (35). In first-episode
patients, more symptoms of depression, longer duration
of untreated psychosis, and positive symptoms, such as
hallucinations and delusions, were found to increase the
odds of experiencing suicidal ideation (36). Another study
found that the severity of negative symptoms was lower
in schizophrenia patients who attempted suicide (37).
With respect to cognitive performance, decreased global
cognitive functioning and visual memory predicted suicidal
behavior in non-affective psychosis (38). In a meta-analysis
and meta-regression analysis in over 80,000 patients with
schizophrenia, depressive symptoms, the Positive and Negative
Symptom Scale (PANSS) general score, and the number of
hospitalizations were higher in patients with suicidal ideation
(39). A history of alcohol use, family history of psychiatric
illness, physical comorbidity, history of depression, and
depressive symptoms were associated with suicide attempts,
whereas poor adherence to treatment, hopelessness, higher
intelligence quotient, history of attempted suicide, and being
male were most consistently associated with completed suicide
(39).
This qualitative review will provide a current overview of
clinical studies aimed at reducing the socioeconomic burden of
schizophrenia and mortality by addressing metabolic risk factors
and symptom severity in schizophrenia patients.
THE METABOLIC SYNDROME IN
SCHIZOPHRENIA
The International Diabetes Federation defines the metabolic
syndrome as a combination of increased waist circumference (a
mandatory feature) and two of the following criteria: elevated
triglycerides, high blood pressure, elevated fasting glucose, and
low high-density lipoprotein (HDL) cholesterol (Table 1) (40).
Metabolic syndrome is defined slightly differently by the Adult
Treatment Panel III (ATP III) of the National Cholesterol
Education Program (41) and the adapted Adult Treatment
Panel III (ATP III-A) of the American Heart Association
(42), both of which require 3 of 5 criteria to be fulfilled
(Table 2). In the general population, the metabolic syndrome
is associated with a 4-fold increased relative risk to develop
type 2 diabetes mellitus (43) and a 2-fold increased relative
TABLE 1 | International Diabetes Federation criteria for metabolic syndrome.
Measure Threshold (Waist circumference plus 2
other measures required)
Elevated waist circumference
Men ≥94 cm
Women ≥80 cm
Elevated triglycerides ≥150 mg/dl
Elevated blood pressure* ≥130mm Hg systolic blood pressure or
≥85mm Hg diastolic blood pressure
Reduced high-density lipoprotein
cholesterol
Men <40 mg/dl
Women <50 mg/dl
Elevated fasting glucose** ≥100 mg/dl
*or treated with antihypertensive medication; **or treated with insulin or hypoglycaemic
medication.
risk to develop CVD, such as stroke and coronary heart
disease (44). Schizophrenia patients have a higher prevalence
of metabolic syndrome than the general population and a
2- to 3-fold increased risk for CVD, resulting in increased
cardiac mortality (30, 45). Metabolic syndrome was present in
37.3% of schizophrenia patients treated with second-generation
antipsychotics and associated with an increased 10-year risk
of coronary heart disease (risk ratio 2.18, 95% CI 1.88–2.48)
in both male and female patients (risk ratio 1.94, 95%
CI 1.65–2.23). Among the criteria for metabolic syndrome,
triglyceride levels and waist circumference were significantly
associated with the 10-year risk of coronary heart disease
events (46). A meta-analysis found that the overall rate of
metabolic syndrome in schizophrenia patients was 32.5% (95%
CI 30.1–35.0%) and showed only minor differences between
treatment settings (inpatient vs. outpatient), country of origin,
and gender. Duration of illness and older age had the strongest
influence. Among the criteria for metabolic syndrome, waist
circumference was the strongest predictor (47). Additionally,
the prevalence of metabolic syndrome was higher in patients
with negative symptoms, which are associated with a sedentary
lifestyle and lack of physical activity (48). Furthermore, in
schizophrenia patients metabolic syndrome was significantly
associated with cognitive impairment and was found to
contribute to cognitive deficits throughout the course of the
disease (49).
One study found that the risk of metabolic syndrome was
elevated in all patients with severe mental illness (32.6%,
95% CI 30.8–34.3%) and did not differ between patients with
schizophrenia and those with bipolar disorder or between
patients with bipolar disorder and those with major depression
(45). In a meta-analysis of first-episode schizophrenia patients,
the rate of metabolic syndrome was only 9.9%; the rate of
overweight was 22%; hypertriglyceridemia, 19.6%; low HDL,
21.9%; hyperglycaemia, 6.4%; high blood pressure 24.3%; and
smoking, 46.8% (50). This indicates that the cardiovascular risk
is lower in first-episode than in multi-episode schizophrenia
patients. Longer duration of illness is also predictive for longer
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TABLE 2 | Adult Treatment Panel III and III-A criteria for metabolic syndrome.
Measure Clinical criteria ATP III
(3 of 5 required)
Threshold ATP III-A
(3 of 5 required)
Elevated waist
circumference
Men ≥102 cm ≥102 cm
Women ≥88 cm ≥88 cm
Elevated triglycerides ≥150 mg/dl ≥150 mg/dl
Elevated blood
pressure
≥130mm Hg systolic blood
pressure or ≥85mm Hg
diastolic blood pressure
≥130mm Hg systolic
blood pressure or
≥85mm Hg diastolic
blood pressure
Reduced high-density
lipoprotein cholesterol
Men <40 mg/dl <40 mg/dl
Women <50 mg/dl <50 mg/dl
Elevated fasting
glucose
≥110 mg/dl ≥100 mg/dl
treatment with antipsychotics, and treatment with second-
generation antipsychotics in particular is a risk factor for
developing metabolic syndrome (see below).
ANTIPSYCHOTIC TREATMENT AND
METABOLIC SYNDROME
Despite reducing positive symptoms, first- and second-
generation antipsychotics have demonstrated only poor or no
efficacy in improving cognitive deficits and negative symptoms
in schizophrenia (51, 52). Depending on the dose, users of
typical and atypical antipsychotics had higher rates of sudden
cardiac death than non-users (adjusted incidence rate 1.99, 95%
CI 1.68–2.34) (53). Furthermore, atypical antipsychotics are
known to prolong the QTc interval and increase resting heart
rate, thereby affecting autonomic neurocardiac function (54).
However, a decrease in heart rate variability has also been shown
in unmedicated schizophrenia patients and is a cardiac risk
factor, together with low physical fitness (55). A meta-analysis
showed that second-generation antipsychotics have fewer
extrapyramidal side effects than first-generation drugs, such as
haloperidol (52). Many of the most effective second-generation
antipsychotics, including olanzapine, clozapine, and risperidone
(52, 56), however, are associated with substantial weight gain
and sedation (52), leading to increased rates of the metabolic
syndrome. In unmedicated and first-episode schizophrenia
patients, the overall rate of the metabolic syndrome was only
about 10%, the rate of diabetes was only 1–2%, and the rate
of overweight was 22–26%. Therefore, the cardiovascular risk
can be assumed to be higher in multi-episode patients with
a long treatment history (50). A meta-analysis found that
patients with severe mental illness who were treated with
any antipsychotic had a significantly higher risk of metabolic
syndrome than antipsychotic-naïve individuals. The risk
was higher with olanzapine and clozapine than with other
antipsychotics, especially aripirazole, and higher in patients
on polypharmacotherapy than in those on monotherapy (45).
Another meta-analysis also found the highest rates of metabolic
syndrome in patients treated with clozapine (51.9%) and the
lowest rates in unmedicated patients (20.2%) (47). One study
found a positive association between a serotonin receptor gene
(HTR2C) polymorphism and metabolic syndrome in patients
treated with olanzapine, clozapine, and risperidone and that
genetic factors may influence the prevalence of the metabolic
syndrome in schizophrenia (57).
In summary, lifestyle changes can be assumed to be
warranted, especially in multi-episode patients on long-term
antipsychotic treatment. To reduce the risk for metabolic
syndrome, subsequent CVD, and mortality, add-on therapeutic
interventions aimed at improving symptoms of the disease, such
as depression or negative symptoms; reducing the smoking rate;
and increasing physical activity are needed (58).
PHYSICAL ACTIVITY IN SCHIZOPHRENIA
A worldwide analysis of adverse health conditions in the
general population estimated that physical inactivity causes 6%
of the burden of disease from coronary heart disease; 7%,
from type 2 diabetes; and 10%, from breast cancer and colon
cancer. Overall, inactivity causes 9% of premature mortality
(59). The health benefits of physical activity in adults include
reduced rates of metabolic syndrome, coronary heart disease,
high blood pressure, type 2 diabetes, stroke, depression, and
cancer. Additionally, there is strong evidence for increased
cardiorespiratory fitness, healthier body mass and composition,
and improved cognitive functioning (59). The high prevalence of
the metabolic syndrome in schizophrenia may be a result of the
disease itself and treatment with antipsychotics (see above) or of
sedentary behavior and low physical activity and aerobic fitness,
which play an important role in this patient group (60, 61), or a
combination of these factors. Studies have repeatedly shown that
schizophrenia patients show reduced cardiovascular fitness and
physical activity (62). In a meta-analysis of 13 studies, sedentary
behavior measured in hours per day was significantly higher
in schizophrenia patients (hedges g = 1.13, 95% CI 1.47–4.1)
than in healthy controls (63). According to a meta-analysis,
schizophrenia patients engage in less moderate (hedges g =
−0.45, 95% CI −0.79 to −0.1) and vigorous physical activity
(g = −0.4, 95% CI −0.60 to −0.18) than healthy controls,
and depressive symptoms and older age are associated with
less vigorous physical activity (64). A meta-analysis of 212
schizophrenia patients and 132 healthy individuals confirmed
that physical activity was lower in the patient group and
showed that decreased physical activity was correlated with
impaired quality of life and social functioning, increased social
withdrawal, and lower motivation and employment rates (65).
Furthermore, low physical fitness was associated with illness
duration, smoking, the presence of the metabolic syndrome,
and more severe negative, depressive, and cognitive symptoms
(26). In schizophrenia patients, the duration of physical activity
was negatively correlated with waist circumference and body
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mass index, while food intake variables correlated with HDL
cholesterol and triglyceride levels (66). A systematic review
found that lifestyle interventions with psychoeducation, diet,
and recommendations on physical activity were associated with
significant weight reduction, reduced bodymass index, decreased
waist circumference, and lower blood glucose levels (67).
REQUIREMENTS FOR AEROBIC
EXERCISE STUDIES IN SCHIZOPHRENIA
Compared with the healthy population, patients with
schizophrenia have specific characteristics that decrease their
motivation to perform physical activity; these characteristics
include sedation related to antipsychotic treatment;
schizophrenia symptoms, including anxiety and depression;
a lower level of education; little experience with exercise; social
withdrawal; and negative symptoms (68, 69). Therefore, it is
essential that aerobic exercise interventions aimed at improving
cardiovascular fitness are supervised by a sports scientist to
increase patients’ motivation to participate (70). Schizophrenia
patients and healthy controls showed comparable adaptations
to endurance training, as assessed by physical working capacity
and maximal achieved power, but differences were found in
changes of performance at a given lactate concentration (70).
Under supervision by a sports scientist, endurance training
was feasible and effective in both groups (70). The first studies
to investigate aerobic exercise in schizophrenia patients had
many methodological limitations (71). Major concerns included
missing healthy or patient control groups or both, inadequate
sample sizes, and non-randomized or non-controlled designs
(72–74). In later endurance training studies, a minimum of
30min per training session and at least three sessions per week
were recommended in schizophrenia patients (75). According
to the criteria of the American College of Sports Medicine, in
healthy individuals 150min of moderate training per week are
necessary to improve cardiorespiratory fitness (76). A recent
cross-sectional study examined the exercise behavior and mental
health of 1,237,194 people aged 18 years or older in the USA and
found that individuals who exercised had 43.2% fewer days of
poor mental health in the past month and a lower mental health
burden than the non-exercising groups. Interestingly, the largest
effects were seen for popular team sports, cycling, and aerobic
and gym activities and for durations of 45min and frequencies
of three to five times per week (77).
EFFECTS OF AEROBIC EXERCISE
INTERVENTIONS ON THE METABOLIC
SYNDROME
New add-on treatment options, such as aerobic exercise,
are needed to reduce the risk of cardiometabolic diseases
in schizophrenia. However, results of intervention studies
examining the effects endurance training on parameters of
the metabolic syndrome in schizophrenia patients were mainly
negative. In a combined Weight Watchers intervention, exercise
had no effects on weight loss (78). A randomized controlled
trial in schizophrenia patients consisting of 2 h of aerobic
exercise per week over a period of 6 months had no effects
on body mass index, body fat percentage, or factors of
the metabolic syndrome (79). A meta-analysis of aerobic
exercise interventions in patients with bipolar or schizophrenia
spectrum disorders found no effects of aerobic exercise on
body weight or body mass index (80), and another meta-
analysis also reported no effects of aerobic exercise on body
mass index in schizophrenia patients (81). In contrast, in a
small sample of schizophrenia patients aerobic exercise improved
physical activity, blood pressure, and body composition (82).
In a randomized study of an intervention comprising aerobic
group exercise and individual weight management sessions in
obese or overweight patients with schizophrenia, schizoaffective
disorder, bipolar disorder, and major depression, weight loss
in the intervention group increased progressively over the 18-
month study period and differed from the control group (83).
In summary, findings to date indicate that isolated exercise
interventions are unlikely to induce weight loss in patients with
schizophrenia (84). However, adding psychosocial interventions
or diet to aerobic exercise programs seem to be a promising
approach to reduce body weight. Increased physical activity
(pedometer walking) plus motivational interviewing reduced
body weight in obese schizophrenia patients after 12 weeks (85).
In obese schizophrenia patients, a 3-month lifestyle intervention
comprising psychosocial treatment, behavior therapy, and
aerobic exercise reduced waist circumference, body weight, and
body mass index but did not affect blood lipids or glucose
levels (86). In a small study in multi-episode schizophrenia
patients, an aerobic exercise program consisting of three 30-
min sessions per week over a period of 24 weeks significantly
reduced weight and body mass index (73). In a personalized
diet and exercise program (3 exercise sessions per week)
in 106 schizophrenia patients treated with antipsychotics,
the months of participation correlated with weight loss (87)
(Table 3).
Because of the need to improve the efficacy of aerobic
exercise, higher intensity training, such as high-intensity interval
training (HIIT), has been used in obese individuals. HIIT is
a promising new method of intensified endurance training.
A 12-week HIIT significantly improved metabolic parameters,
such as waist circumference, body mass, fasting glucose, HDL
cholesterol, and blood pressure, in mentally healthy patients
with cardiometabolic risk factors and obesity (94–98). HIT has
the highest potential to reduce visceral adipose tissue in obese
individuals (99). Compared with continuous training, HIIT
significantly reduced insulin resistance, HbA1c, and body weight
in healthy adults and reduced fasting glucose in participants at
risk of type 2 diabetes (100). However, a recent meta-analysis
found no difference between HIIT and moderate-intensity
continuous training for body fat reduction (101). This finding
was supported by a meta-analysis of 12-month interventions in
obese adults, which showed weight loss but found no difference
between HIIT and moderate-intensity exercise (102). Another
meta-analysis showed that HIIT performed as cycling or running
significantly reduced abdominal and visceral fat mass but that
running was more effective than cycling (103). In a group of
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obese men, HIIT significantly improved insulin sensitivity and
muscle mitochondrial content (increased muscle mitochondrial
content is assumed to be a basic mechanism of effect of HIIT)
compared with continuous aerobic training (104). To date, only
two studies have applied HIIT interventions in patients with
schizophrenia. One evaluated a 14-week program of 40min
HIIT twice a week in first-episode patients and showed a
significant decrease in waist circumference and heart rate (105).
The other studied an 8-week HIIT program comprising 25-
min sessions three times a week in multi-episode patients and
showed reduced body weight, body mass index, and resting
heart rate (106) (Table 4). Overall, HIIT has the potential to
improve parameters of the metabolic syndrome in patients with
schizophrenia.
EFFECTS OF AEROBIC EXERCISE
INTERVENTIONS ON
CARDIORESPIRATORY FITNESS
In the general population, improving cardiorespiratory fitness
is a key factor in preventing CVD and mortality (110, 111).
Cardiorespiratory fitness can be measured by the highest
oxygen intake (referred to as VO2max or VO2peak) and peak
work rate/power output (Wpeak). Aerobic exercise interventions
seeking to improve cardiorespiratory fitness can prevent
CVD and the associated mortality (112). In a randomized
study in obese and overweight patients with severe mental
illness, including schizophrenia, schizoaffective disorder, bipolar
disorder, and major depression, participation in group exercise
classes was associated with improved short- and long-term
cardiorespiratory fitness, as indicated by a lower heart rate
response (92). Significant increases in VO2max, as a measure
of aerobic capacity, and power output (Wpeak) have been
reported in schizophrenia patients after continuous exercise
training compared with control conditions, such as occupational
therapy or table soccer (73, 79, 82, 88, 89, 91, 113) (Table 3).
In a meta-analysis, cardiorespiratory fitness was improved in
schizophrenia patients after aerobic exercise (g = 0.43, 95%
CI 0.05–0.82). Furthermore, in schizophrenia patients improved
cardiorespiratory fitness was correlated with an increased volume
of the hippocampus (88, 114), with decreased ventricular and
increased cerebral gray matter volume, and with thickening in
the frontal, temporal, and cingulate cortex of the left hemisphere
(113).
In a meta-analysis of HIIT vs. moderate-intensity continuous
training, HIIT was more likely to increase VO2peak in adults
with coronary heart disease, hypertension, metabolic syndrome,
and obesity (115). In obese adults with hypertension, HIIT and
continuous training both improved cardiorespiratory fitness,
whereby an exercise intervention lasting at least 12 or 16 weeks
was needed to achieve these effects (116). In schizophrenia
patients, HIIT improved VO2peak by 12% compared with playing
computer games (107), and in a case report of a patient
with schizophrenia HIIT was more effective than moderate
continuous training in increasing heart rate variability and
reduing resting heart rate (109). A decrease in resting heart rate
and 38% increase in VO2max was detected after a 14-week HIT
program in schizophrenia patients (105). In summary, aerobic
exercise is capable of improving cardiorespiratory fitness and
thereby reducing risk factors for CVD and associated mortality
(Table 4).
TABLE 4 | Effects of high-intensity interval training on metabolic risk factors and symptoms of the disease in patients with schizophrenia.
Study Participants Training
methods
Effects on cardio-
respiratory fitness
Effects on metabolic
partameters
Effects on symptoms
Heggelund et al. (107) 25 inpatients 8 weeks HIIT vs.
playing computer
games
VO2peak ↑ No change in positive,
negative symptoms or
depression
Abdel-Baki et al. (105) 25 first-episode patients 14 week HIIT VO2max ↑
Resting heart rate ↓
Waist circumference ↓
Body weight -
Body mass index
Heggelund et al. (108) 20 patients with
schizophrenia, 13 patients
with depression, 20
healthy individuals
1 day HIIT Positive affect in all
participants Patients with
depression and
schizophrenia had reduced
distress and state anxiety
Herbsleb et al. (109) Case report in one patient
with schizophrenia
6 weeks HIIT vs.
CET
Resting heart rate ↓
Heart rate variability ↑
VO2peak ↑
Body weight -
Body mass index –
Body fat percentage -
Wu et al. (106) 20 patients with chronic
schizophrenia
8 weeks HIIT Resting heart rate ↓
Pulse pressure ↓
Mean arterial
pressure ↑
Diastolic blood
pressure ↑
Body weight ↓
Body mass index ↓
Negative symptoms
improved. General
psychopathology improved.
Depression and anxiety
improved
HIIT, high intensity interval training; CET, continuous endurance training; VO2peak, VO2max, highest oxygen intake.
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THE IMPACT OF AEROBIC EXERCISE ON
SCHIZOPHRENIA SYMPTOMS AND
COGNITION
Reduction of symptoms may help to decrease suicidality in
patients with schizophrenia (see above), and there is evidence
that aerobic exercise interventions can improve schizophrenia
symptoms and cognitive deficits. Published data from our
group show that a structured endurance training programme is
feasible in multi-episode schizophrenia patients (70). Previously,
we demonstrated that 3 x 30min aerobic exercise per week
alleviated negative symptoms, significantly improved short-term
memory and increased hippocampal volumes in patients with
schizophrenia (88). Furthermore, when we added cognitive
training to aerobic exercise from week 6 up to 3 months negative
symptoms and working memory improved (90). Importantly, in
45% of the multi-episode schizophrenia patients who performed
aerobic exercise the Global Assessment of Functioning (GAF)
score improved by about 20% from baseline to month 3
(90); thus, this study showed that aerobic exercise as add-on
therapy fosters patients’ capacity to improve in multi-epsode
schizophrenia. In this study, we did not replicate the increase
of hippocampal volume after aerobic exercise, although we did
detect increased volume of the left temporal cortex (117). In a
randomized clinical trial, a 6-month structured aerobic exercise
intervention reduced total symptoms of schizophrenia, positive
symptoms, disorganization, excitement, emotional distress,
symptoms of depression, and need of care significantly more
than occupational therapy (79). In first-episode patients, an
individualized exercise training program revealed improvement
of negative and positive symptoms, psychosocial functioning and
verbal short-term memory (93).
The beneficial effects of physical exercise on brain function
and structure and cognitive performance have been repeatedly
reported in healthy individuals [e.g., (118)]. Beyond this, a meta-
analysis showed that in schizophrenia patients aerobic exercise
improves negative, positive, and depressive symptoms and global
functioning, as measured by the GAF (119). Another meta-
analysis focusing on cognition demonstrated improved global
cognition, working memory, social cognition, and attention
after aerobic exercise in schizophrenia patients (120). Findings
from the literature are contradictory, but a meta-analysis of
exercise interventions in schizophrenia indicated that symptoms
improve with a higher intensity of training (81). Symptom
improvement was prominent in interventions of 90min of
moderate exercise per week (81). In healthy adults, elderly people,
or individuals with obesity, HIIT improved executive function
and verbal and short-term memory (95, 121). A meta-analysis
in healthy normal-weight and obese individuals showed that
HIIT training improved affective psychological responses (122).
In a first study in a small group of patients with different
diagnoses that included only some schizophrenia patients, 8
weeks of HIIT did not decrease psychopathological symptoms,
but it did have positive effects on physical fitness and anxiety
(107, 108). In 18 patients with schizophrenia, an 8-week HIIT
program significantly improved negative symptoms, general
psychopathology, depression, and anxiety (106) (Table 4).
CONCLUSION
In summary, add-on therapy of endurance training combined
with psychosocial interventions or diet may improve symptoms
of the metabolic syndrome in schizophrenia patients, thereby
reducing the prevalence of CVD and mortality. It has been
shown that aerobic exercise programs are feasible in populations
with severe mental illness and are accepted by schizophrenia
patients who have weight gain and reduced physical fitness.
However, specific complicating characteristics of patients with
schizophrenia in comparison to the healthy population include
fatigue and sedation (e.g., due to antipsychotic treatment),
symptoms of the disease, a high level of anxiety and depression,
antipsychotic-induced weight gain, a lower level of education,
little experience with sport, and a lack of motivation for
physical activity in case of negative symptoms (70). To increase
patients’ motivation to adhere to training sessions, a sports
scientist must provide supervision, which in turn increases the
cost of otherwise cheap training methods, such as biking and
walking. Nevertheless, aerobic exercise programs still have a good
cost-benefit ratio when one considers the high socioeconomic
costs of metabolic risk factors in these patients. To date,
physical exercise has no known serious side effects or safety
issues that might pose any risk to the patients. Aerobic
exercise can significantly contribute to improving symptoms
of the disease, including cognitive deficits and psychosocial
functioning. In addition, it may have positive effects on the
residual symptoms that are known to be treatment resistant even
after long-term therapy with antipsychotics; however, treatment
recommendations will be given when the optimal dose and
duration of the intervention has been found in randomized
clinical trials. The reversibility of structural alterations in the
brain and improvement of symptoms suggest that aerobic
exercise may induce a regenerative process in patients with
schizophrenia (123). Finally, HIIT can be hypothesized to have
greater potential than conventional, aerobic endurance training
to improve cognitive deficits, overall symptoms, and metabolic
parameters in schizophrenia patients. Future studies should
investigate the effects of HIIT on neuroplastic changes in the
brain. Furthermore, treatment recommendations should include
aerobic exercise in multimodal therapy regimes. The German S3
guideline “Schizophrenia” (124) and the NICE guideline (125)
recommend exercise programs for patients with schizophrenia
and weight gain. However, positive effects of aerobic exercise
may be limited to the training periods (90), and long-term
improvement of metabolic risk factors may require continuation
of aerobic training in certified sports clubs. Overall, further high
quality clinical trials are needed before statements can be made
about the optimal length and type of aerobic exercise programs
for routine clinical care.
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